Research suggests stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models and lead to better treatment for non-small cell lung cancer.
The modeling study looks at the benefits and harms associated with various low-dose computed tomography screening strategies—identifying those that result in the most benefits for a given level of screening.
A new inhibitor designed to target what’s been called an “undruggable” genetic mutation showed promising activity against advanced cancers with this mutation.